

## SEMINARI

# "ZeCardio: a versatile platform for cardiovascular drug and target discovery"

**Dr. Javier Terriente, PhD**

Chief Scientific Officer, Zeclinics (Barcelona)

**Data:** 28 de novembre de 2018

**Hora:** 11:30 hores

**Lloc:** aula 0.22, planta baixa Unitat Docent

ZeClinics is a Biotech Contract Research Organization (CRO) and early-phase biopharmaceutical (PHARMA) company using zebrafish for: 1) performing target validation, 2) developing disease models for several indications and 3) addressing the safety and efficacy of novel chemical molecules. ZeClinics' business strength relies on high scientific expertise and top-notch research facilities, combined with strategic industrial partnerships and academic collaborations. The aim of the company is to challenge the traditional drug discovery pipeline by offering an economic, fast and robust array of customized assays, designed to address the safety and biomedical relevance of novel molecules. Another strength is the use of genome editing technologies, such as CRISPR, for performing target validation and developing innovative disease model. In addition to the CRO activity, Zeclinics is developing different drug discovery pipelines in the cardiovascular field.

**Agenda:** Dra. Glòria Arqué, Neurociències clíniques, IRBLleida